Trial Profile
A Phase 3, Multicenter, Long-term Observational Study Of Subjects From Tanezumab Studies Who Undergo A Total Knee, Hip Or Shoulder Replacement
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 31 Jul 2020
Price :
$35
*
At a glance
- Drugs Tanezumab (Primary) ; Celecoxib; Diclofenac; Naproxen
- Indications Musculoskeletal pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms TJR-FOLLOW-UP
- Sponsors Pfizer
- 24 Jul 2019 Status changed from recruiting to completed.
- 19 Jul 2019 Planned End Date changed from 19 Jul 2019 to 15 Jul 2019.
- 19 Jul 2019 Planned primary completion date changed from 19 Jul 2019 to 15 Jul 2019.